Compare MLP & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | XFOR |
|---|---|---|
| Founded | 1909 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.9M | 377.3M |
| IPO Year | 2010 | N/A |
| Metric | MLP | XFOR |
|---|---|---|
| Price | $17.36 | $4.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 13.3K | ★ 571.4K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,457,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.24 | N/A |
| 52 Week Low | $13.84 | $1.35 |
| 52 Week High | $20.34 | $4.83 |
| Indicator | MLP | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 55.55 |
| Support Level | $16.38 | $3.54 |
| Resistance Level | $17.57 | $4.51 |
| Average True Range (ATR) | 0.58 | 0.22 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 26.55 | 79.22 |
Maui Land & Pineapple Co Inc is a landholding and operating parent company that owns land and commercial property on the island of Maui, Hawaii. The Company puts its assets into productive use by planning, managing, developing, and selling residential, resort, commercial, agricultural, and industrial real estate. Its segments include land development and sales, which cover land planning, entitlement, development, construction, and sales of land assets; leasing, which generates revenue from real property leasing, license fees and royalties, and includes maintenance of real estate assets, conservation activities, and management of water systems in West and Upcountry Maui; and resort amenities, which include a membership program offering benefits within the Kapalua Resort.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.